Cargando…

Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease

BACKGROUND: Glial fibrillary acidic protein (GFAP) is expressed by astrocytes in the central nervous system (CNS), but also by immature and regenerative Schwann cells in the peripheral nervous system (PNS). GFAP antibodies (GFAP-Abs) in cerebrospinal fluid (CSF) have been mainly described in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Theuriet, Julian, Cluse, Florent, Gravier-Dumonceau, Alice, Picard, Géraldine, Closs, Sterenn, Rogemond, Véronique, Timestit, Noémie, Bouhour, Françoise, Petiot, Philippe, Davy, Vincent, Chanson, Eve, Arzalluz-Luque, Joaquín, Marignier, Romain, Honnorat, Jerome, Pegat, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576672/
https://www.ncbi.nlm.nih.gov/pubmed/37540278
http://dx.doi.org/10.1007/s00415-023-11908-7
_version_ 1785121165117751296
author Theuriet, Julian
Cluse, Florent
Gravier-Dumonceau, Alice
Picard, Géraldine
Closs, Sterenn
Rogemond, Véronique
Timestit, Noémie
Bouhour, Françoise
Petiot, Philippe
Davy, Vincent
Chanson, Eve
Arzalluz-Luque, Joaquín
Marignier, Romain
Honnorat, Jerome
Pegat, Antoine
author_facet Theuriet, Julian
Cluse, Florent
Gravier-Dumonceau, Alice
Picard, Géraldine
Closs, Sterenn
Rogemond, Véronique
Timestit, Noémie
Bouhour, Françoise
Petiot, Philippe
Davy, Vincent
Chanson, Eve
Arzalluz-Luque, Joaquín
Marignier, Romain
Honnorat, Jerome
Pegat, Antoine
author_sort Theuriet, Julian
collection PubMed
description BACKGROUND: Glial fibrillary acidic protein (GFAP) is expressed by astrocytes in the central nervous system (CNS), but also by immature and regenerative Schwann cells in the peripheral nervous system (PNS). GFAP antibodies (GFAP-Abs) in cerebrospinal fluid (CSF) have been mainly described in patients with meningoencephalomyelitis. We aimed to study PNS symptoms in patients with CSF GFAP-Abs. METHODS: We retrospectively included all patients tested positive for GFAP-Abs in the CSF by immunohistochemistry and confirmed by cell-based assay expressing human GFAPα since 2017, from two French reference centers. RESULTS: In a cohort of 103 CSF GFAP-Abs patients, 25 (24%) presented with PNS involvement. Among them, the median age at onset was 48 years and 14/25 (56%) were female. Abnormal electroneuromyography was observed in 11/25 patients (44%), including eight isolated radiculopathies, one radiculopathy associated with polyneuropathy, one radiculopathy associated with sensory neuronopathy, and one demyelinating polyradiculoneuropathy. Cranial nerve involvement was observed in 18/25 patients (72%). All patients except one had an associated CNS involvement. The first manifestation of the disease concerned the PNS in three patients. First-line immunotherapy was administered to 18/24 patients (75%). The last follow-up modified Rankin Scale was ≤ 2 in 19/23 patients (83%). Patients with PNS involvement had significantly more bladder dysfunction than patients with isolated CNS involvement (68 vs 40.3%, p = 0.031). CONCLUSIONS: PNS involvement in GFAP-Abs autoimmunity is heterogeneous but not rare and is mostly represented by acute or subacute cranial nerve injury and/or lower limb radiculopathy. Rarely, PNS involvement can be the first manifestation revealing the disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-023-11908-7.
format Online
Article
Text
id pubmed-10576672
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-105766722023-10-16 Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease Theuriet, Julian Cluse, Florent Gravier-Dumonceau, Alice Picard, Géraldine Closs, Sterenn Rogemond, Véronique Timestit, Noémie Bouhour, Françoise Petiot, Philippe Davy, Vincent Chanson, Eve Arzalluz-Luque, Joaquín Marignier, Romain Honnorat, Jerome Pegat, Antoine J Neurol Original Communication BACKGROUND: Glial fibrillary acidic protein (GFAP) is expressed by astrocytes in the central nervous system (CNS), but also by immature and regenerative Schwann cells in the peripheral nervous system (PNS). GFAP antibodies (GFAP-Abs) in cerebrospinal fluid (CSF) have been mainly described in patients with meningoencephalomyelitis. We aimed to study PNS symptoms in patients with CSF GFAP-Abs. METHODS: We retrospectively included all patients tested positive for GFAP-Abs in the CSF by immunohistochemistry and confirmed by cell-based assay expressing human GFAPα since 2017, from two French reference centers. RESULTS: In a cohort of 103 CSF GFAP-Abs patients, 25 (24%) presented with PNS involvement. Among them, the median age at onset was 48 years and 14/25 (56%) were female. Abnormal electroneuromyography was observed in 11/25 patients (44%), including eight isolated radiculopathies, one radiculopathy associated with polyneuropathy, one radiculopathy associated with sensory neuronopathy, and one demyelinating polyradiculoneuropathy. Cranial nerve involvement was observed in 18/25 patients (72%). All patients except one had an associated CNS involvement. The first manifestation of the disease concerned the PNS in three patients. First-line immunotherapy was administered to 18/24 patients (75%). The last follow-up modified Rankin Scale was ≤ 2 in 19/23 patients (83%). Patients with PNS involvement had significantly more bladder dysfunction than patients with isolated CNS involvement (68 vs 40.3%, p = 0.031). CONCLUSIONS: PNS involvement in GFAP-Abs autoimmunity is heterogeneous but not rare and is mostly represented by acute or subacute cranial nerve injury and/or lower limb radiculopathy. Rarely, PNS involvement can be the first manifestation revealing the disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-023-11908-7. Springer Berlin Heidelberg 2023-08-04 2023 /pmc/articles/PMC10576672/ /pubmed/37540278 http://dx.doi.org/10.1007/s00415-023-11908-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Communication
Theuriet, Julian
Cluse, Florent
Gravier-Dumonceau, Alice
Picard, Géraldine
Closs, Sterenn
Rogemond, Véronique
Timestit, Noémie
Bouhour, Françoise
Petiot, Philippe
Davy, Vincent
Chanson, Eve
Arzalluz-Luque, Joaquín
Marignier, Romain
Honnorat, Jerome
Pegat, Antoine
Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease
title Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease
title_full Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease
title_fullStr Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease
title_full_unstemmed Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease
title_short Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease
title_sort peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (gfap) antibody-related disease
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576672/
https://www.ncbi.nlm.nih.gov/pubmed/37540278
http://dx.doi.org/10.1007/s00415-023-11908-7
work_keys_str_mv AT theurietjulian peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT cluseflorent peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT gravierdumonceaualice peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT picardgeraldine peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT closssterenn peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT rogemondveronique peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT timestitnoemie peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT bouhourfrancoise peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT petiotphilippe peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT davyvincent peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT chansoneve peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT arzalluzluquejoaquin peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT marignierromain peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT honnoratjerome peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease
AT pegatantoine peripheralnervoussysteminvolvementaccompaniescentralnervoussysteminvolvementinantiglialfibrillaryacidicproteingfapantibodyrelateddisease